<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82757">
  <stage>Registered</stage>
  <submitdate>14/04/2008</submitdate>
  <approvaldate>8/05/2008</approvaldate>
  <actrnumber>ACTRN12608000237381</actrnumber>
  <trial_identification>
    <studytitle>Detection of exogenous insulin in blood and urine in type I diabetics and non diabetics.</studytitle>
    <scientifictitle>Detection of exogenous insulin (in blood and urine) as a doping agent in 6 type I diabetics and 6 non diabetics, both male and female, aged 18 to 45.  An open label cross over study.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Sports doping detection</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Normal metabolism and endocrine development and function</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Type I diabetic participants take their usual insulin dose and provide blood and urine samples at baseline and for up to 24 hours.
Non diabetic participants are administered intravenous (IV) Actrapid insulin 0.05iu/kg at visit 1, 70g oral glucose at visit 2 and placebo at visit 3.  Blood and urine samples are collected at each visit at baseline then for up to 24 hours. There is a 5 day washout period between visit 1 (insulin administration) and visit 2 (glucose administration).  There is no specified washout period between visit 2 and visit 3 (placebo administration).</interventions>
    <comparator>Acting as their own controls, and non diabetics are compared with diabetics re: metabolism of exogenous insulin.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Bioassay measurement of exogenous insulin levels in blood and urine in both groups of participants.</outcome>
      <timepoint>Samples of blood and urine are taken at baseline and at intervals over 24 hours at each visit.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>None</outcome>
      <timepoint>None</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Type I diabetics:
on insulin therapy
Male or female
Aged 18 to 45.
Non diabetics:
Healthy 
Male or female
Aged 18 to 45</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>In non diabetic group:
Coronary artery disease
epilepsy
diabetes
elite athletes
pregnancy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures>The non diabetic particpants were in the interventional crossover design.
The diabetics were observed following administration of usual clinical treatment</designfeatures>
    <endpoint>Pharmacokinetics / pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>1/10/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>12</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Concord Repatriation General Hospital</primarysponsorname>
    <primarysponsoraddress>Hospital Road Concord NSW 2139</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>World Anti Doping Agency (WADA)</fundingname>
      <fundingaddress>World Anti-doping Agency (WADA)
Stock Exchange Tower
800 Place Victoria (Suite 1700)
PO Box 120
Montreal Canada</fundingaddress>
      <fundingcountry>Canada</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Sports anti doping study. The aim of the study is to obtain specimens of urine and blood from voluneers who have been given an injection of insulin.  These samples will then be used to develop tests which will help detect the presence of insulin in the blood and urine of elite athletes who have used insulin illicitly to enhance their performance.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Concord Hospital HREC</ethicname>
      <ethicaddress>Concord Hospital
Hospital Road
Concord
NSW 2139</ethicaddress>
      <ethicapprovaldate>21/08/2007</ethicapprovaldate>
      <hrec>CH62/6/2006-066 - P Liu</hrec>
      <ethicsubmitdate>10/08/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Peter Liu</name>
      <address>Dept of Andrology
Concord Hospital
Concord NSW 2139</address>
      <phone>02 9767 7222</phone>
      <fax>02 9767 7221</fax>
      <email>pliu@mail.med.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Peter Liu</name>
      <address>Dept of Andrology
Building 22
Concord Hospital
Hospital Road
Conocrd NSW 2139</address>
      <phone>02 9767 7222</phone>
      <fax>02 9767 7221</fax>
      <email>pliu@mail.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Amanda Idan</name>
      <address>Dept of Andrology
Concord Hospital
Conocrd NSW 2139</address>
      <phone>02 9767 7222</phone>
      <fax>02 9767 7221</fax>
      <email>aidan@med.usyd.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>